Investment Analysts’ Weekly Ratings Updates for Maplight Therapeutics (MPLT)

A number of research firms have changed their ratings and price targets for Maplight Therapeutics (NASDAQ: MPLT):

• 8/10/2026 – Maplight Therapeutics was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $13.00 price target on the stock, down from $52.00.
• 8/1/2026 – Maplight Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 7/28/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by Craig Hallum. They now have a $25.00 price target on the stock.
• 7/28/2026 – Maplight Therapeutics had its price target lowered by Canaccord Genuity Group Inc. from $43.00 to $24.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Maplight Therapeutics had its price target lowered by HC Wainwright from $45.00 to $26.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Maplight Therapeutics had its “equal weight” rating reaffirmed by Morgan Stanley. They now have a $21.00 price target on the stock, down from $34.00.
• 7/27/2026 – Maplight Therapeutics had its “outperform” rating reaffirmed by Wolfe Research. They now have a $30.00 price target on the stock.
• 7/27/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 7/24/2026 – Maplight Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $35.00 to $43.00. They now have a “buy” rating on the stock.
• 7/21/2026 – Maplight Therapeutics had its price target raised by UBS Group AG from $48.00 to $52.00. They now have a “buy” rating on the stock.
• 7/20/2026 – Maplight Therapeutics is now covered by BMO Capital Markets. They set an “outperform” rating and a $46.00 price target on the stock.
• 7/20/2026 – Maplight Therapeutics was upgraded by BMO Capital Markets to “strong-buy”.
• 7/13/2026 – Maplight Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/10/2026 – Maplight Therapeutics was upgraded by Wolfe Research to “strong-buy”.
• 7/10/2026 – Maplight Therapeutics had its price target raised by Needham & Company LLC from $42.00 to $45.00. They now have a “buy” rating on the stock.
• 6/24/2026 – Maplight Therapeutics is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $46.00 price target on the stock.
• 6/24/2026 – Maplight Therapeutics was upgraded by Raymond James Financial, Inc. to “strong-buy”.
• 6/23/2026 – Maplight Therapeutics had its price target lowered by Craig Hallum from $43.00 to $40.00. They now have a “buy” rating on the stock.
• 6/22/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by Benchmark Co..
• 6/22/2026 – Maplight Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 6/22/2026 – Maplight Therapeutics had its price target raised by Needham & Company LLC from $37.00 to $42.00. They now have a “buy” rating on the stock.

Insider Transactions at Maplight Therapeutics

In related news, CEO Christopher A. Kroeger sold 118,235 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $27.19, for a total transaction of $3,214,809.65. Following the completion of the sale, the chief executive officer directly owned 1,394,094 shares in the company, valued at approximately $37,905,415.86. This trade represents a 7.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Troy Cox acquired 15,620 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was bought at an average price of $9.52 per share, for a total transaction of $148,702.40. Following the purchase, the director owned 15,620 shares in the company, valued at approximately $148,702.40. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 3.80% of the stock is owned by insiders.

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.